Seres Therapeutics (MCRB) Notes Payables (2014 - 2022)

Seres Therapeutics (MCRB) posted Notes Payables of $456000.0 for Q4 2022, down 95.12% sequentially from $9.3 million in Q3 2021.

Seres Therapeutics (MCRB) Notes Payables (2014 - 2022) Analysis & Trends

Seres Therapeutics has reported Notes Payables for 5 years, with the latest figure at $456000.0 in Q4 2022.

Quarterly Notes Payables changed N/A year-over-year to $456000.0 in Q4 2022, while the trailing twelve-month figure through Dec 2022 was $456000.0 (changed N/A YoY) and the FY2022 annual result came in at $456000.0, changed N/A from the prior year.
Notes Payables declined to $456000.0 in Q4 2022 per MCRB's latest filing, from $9.3 million in the prior quarter.
Over five years, Notes Payables peaked at $9.3 million in Q3 2021 and troughed at $454000.0 in Q4 2020.
A 3-year average of $4.0 million and a median of $3.3 million in 2021 frame the typical range for Notes Payables.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	138.57 Bn	130.72 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	85.99 Bn	77.99 Bn	3.93 Bn
3	Argenx Se	65.00 Bn	59.82 Bn	1.37 Bn
4	Moderna	56.27 Bn	51.13 Bn	52.00 Mn
5	BeOne Medicines	42.00 Bn	36.90 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	31.60 Bn	28.29 Bn	992.69 Mn
7	BioNTech SE	27.68 Bn	9.29 Bn	668.28 Mn
8	Insmed	27.43 Bn	26.27 Bn	358.27 Mn
9	Royalty Pharma	27.34 Bn	26.51 Bn	-
10	Seres Therapeutics	44.16 Mn	44.16 Mn	-

Download Data